Histological comparison between predictive value of preoperative 3-T multiparametric MRI and
Aged
Aged, 80 and over
Edetic Acid
/ analogs & derivatives
Gallium Isotopes
Gallium Radioisotopes
Humans
Lymph Node Excision
Lymph Nodes
/ diagnostic imaging
Lymphatic Metastasis
/ diagnostic imaging
Male
Middle Aged
Multiparametric Magnetic Resonance Imaging
Neoplasm Grading
Neoplasm Invasiveness
Nomograms
Oligopeptides
Positron Emission Tomography Computed Tomography
/ methods
Predictive Value of Tests
Probability
Prospective Studies
Prostatectomy
Prostatic Neoplasms
/ diagnostic imaging
Radiopharmaceuticals
Retrospective Studies
#PCSM
#ProstateCancer
MRI prostate
PET PSMA scan
metastasis
pelvic lymph node
primary staging
prostate cancer
Journal
BJU international
ISSN: 1464-410X
Titre abrégé: BJU Int
Pays: England
ID NLM: 100886721
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
pubmed:
12
6
2020
medline:
27
4
2021
entrez:
12
6
2020
Statut:
ppublish
Résumé
To evaluate the ability of preoperative multiparametric magnetic resonance imaging (mpMRI) and a gallium-68 prostate-specific membrane antigen positron emission tomography/computed tomography ( Between July 2014 and September 2019 only men who had both a preoperative mpMRI and staging A total of 233 consecutive men met the inclusion criteria of which 58 men (24.9%) had a LNM identified on PLND histology. The median (range) International Society of Urological Pathology (ISUP) Grade was 5 (1-5) and the median (range) prostate-specific antigen level was 7.4 (1.5-72) ng/mL. The median (range) number of resected lymph nodes was 16 (1-53) and the median (range) number of positive nodes identified on histology was 2 (1-22). Seminal vesicle invasion on mpMRI was more common in node-positive men than in the absence of LNM (31% vs 12%). The maximum standardised uptake value of the primary tumour on Preoperative
Substances chimiques
Gallium Isotopes
0
Gallium Radioisotopes
0
Oligopeptides
0
Radiopharmaceuticals
0
gallium 68 PSMA-11
0
Edetic Acid
9G34HU7RV0
Types de publication
Comparative Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71-79Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2020 The Authors BJU International © 2020 BJU International Published by John Wiley & Sons Ltd.
Références
Pierorazio PM, Gorin MA, Ross AE et al. Pathological and oncologic outcomes for men with positive lymph nodes at radical prostatectomy: the Johns Hopkins Hospital 30-year experience. Prostate 2013; 73: 1673-80
Hovels AM, Heesakkers RA, Adang EM et al. The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis. Clin Radiol 2008; 63: 387-95
Briganti A, Abdollah F, Nini A et al. Performance characteristics of computed tomography in detecting lymph node metastases in contemporary patients with prostate cancer treated with extended pelvic lymph node dissection. Eur Urol 2012; 61: 1132-8
Brembilla G, Dell'Oglio P, Stabile A et al. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with extended pelvic lymph node dissection. Eur Radiol 2018; 28: 1969-76
Meredith G, Wong D, Yaxley J et al. The use of (68) Ga-PSMA PET CT in men with biochemical recurrence after definitive treatment of acinar prostate cancer. BJU Int 2016; 118(Suppl 3): 49-55
Raveenthiran S, Yaxley J, Gianduzzo T et al. The use of (68)Ga-PET/CT PSMA to determine patterns of disease for biochemically recurrent prostate cancer following primary radiotherapy. Prostate Cancer Prostatic Dis 2019; 22: 385-90
Perera M, Papa N, Christidis D et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol 2016; 70: 926-37
Hofman MS, Lawrentschuk N, Francis RJ et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 2020; 395: 1208-16
Yaxley JW, Raveenthiran S, Nouhaud FX et al. Risk of metastatic disease on (68) gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int 2019; 124: 401-7
Mottet N, Bellmunt J, Bolla M et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017; 71: 618-29
Mohler JL, Antonarakis ES, Armstrong AJ et al. Prostate Cancer, Version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019; 17: 479-505
Yaxley JW, Dagher J, Delahunt B, Egevad L, Srigley J, Samaratunga H. Reconsidering the role of pelvic lymph node dissection with radical prostatectomy for prostate cancer in an era of improving radiological staging techniques. World J Urol 2018; 36: 15-20
Briganti A, Chun FK, Salonia A et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol 2006; 50: 1006-13
Bandini M, Marchioni M, Pompe RS et al. First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU Int 2018; 121: 592-9
Gandaglia G, Ploussard G, Valerio M et al. A novel nomogram to identify candidates for extended pelvic lymph node dissection among patients with clinically localized prostate cancer diagnosed with magnetic resonance imaging-targeted and systematic biopsies. Eur Urol 2019; 75: 506-14
Cooperberg MR, Pasta DJ, Elkin EP et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 2005; 173: 1938-42
Wu X, Reinikainen P, Vanhanen A et al. Correlation between apparent diffusion coefficient value on diffusion-weighted MR imaging and Gleason score in prostate cancer. Diagn Interv Imaging 2017; 98: 63-71
Surov A, Meyer HJ, Wienke A. Correlation between apparent diffusion coefficient (ADC) and cellularity is different in several tumors: a meta-analysis. Oncotarget 2017; 8: 59492-9
Gaunay G, Patel V, Shah P et al. Role of multi-parametric MRI of the prostate for screening and staging: experience with over 1500 cases. Asian J Urol 2017; 4: 68-74
de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM. Accuracy of magnetic resonance imaging for local staging of prostate cancer: a diagnostic meta-analysis. Eur Urol 2016; 70: 233-45
Woythal N, Arsenic R, Kempkensteffen C et al. Immunohistochemical validation of PSMA expression measured by (68)Ga-PSMA PET/CT in primary prostate cancer. J Nucl Med 2018; 59: 238-43
von Klot CJ, Merseburger AS, Boker A et al. (68)Ga-PSMA PET/CT imaging predicting intraprostatic tumor extent, extracapsular extension and seminal vesicle invasion prior to radical prostatectomy in patients with prostate cancer. Nucl Med Mol Imaging 2017; 51: 314-22
Demirci E, Kabasakal L, Sahin OE et al. Can SUVmax values of Ga-68-PSMA PET/CT scan predict the clinically significant prostate cancer? Nucl Med Commun 2019; 40: 86-91
Park SY, Shin SJ, Jung DC et al. PI-RADS version 2: preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer. Eur J Radiol 2017; 91: 22-8
Donati OF, Afaq A, Vargas HA et al. Prostate MRI: evaluating tumor volume and apparent diffusion coefficient as surrogate biomarkers for predicting tumor Gleason score. Clin Cancer Res 2014; 20: 3705-11
Yaxley JW, Raveenthiran S, Nouhaud FX et al. Outcomes of primary lymph node staging of intermediate and high risk prostate cancer with (68)Ga-PSMA positron emission tomography/computerized tomography compared to histological correlation of pelvic lymph node pathology. J Urol 2019; 201: 815-20
Uprimny C, Kroiss AS, Decristoforo C et al. (68)Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44: 941-9
Wu H, Xu T, Wang X et al. Diagnostic performance of (6)(8)gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J Mens Health 2019; 38: 208-19
Tulsyan S, Das CJ, Tripathi M, Seth A, Kumar R, Bal C. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Nucl Med Commun 2017; 38: 1094-102
Petersen LJ, Nielsen JB, Langkilde NC et al. (68)Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World J Urol 2020; 38: 939-48
Zhang Q, Zang S, Zhang C et al. Comparison of (68)Ga-PSMA-11 PET-CT with mpMRI for preoperative lymph node staging in patients with intermediate to high-risk prostate cancer. J Transl Med 2017; 15: 230
Gupta M, Choudhury PS, Hazarika D, Rawal S. A comparative study of (68)Gallium-prostate specific membrane antigen positron emission tomography-computed tomography and magnetic resonance imaging for lymph node staging in high risk prostate cancer patients: an initial experience. World J Nucl Med 2017; 16: 186-91
Fossati N, Willemse PM, Van den Broeck T et al. The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: a systematic review. Eur Urol 2017; 72: 84-109
Abdollah F, Suardi N, Gallina A et al. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. Ann Oncol 2013; 24: 1459-66
Touijer KA, Mazzola CR, Sjoberg DD, Scardino PT, Eastham JA. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur Urol 2014; 65: 20-5
Greer MD, Shih JH, Lay N et al. Interreader variability of prostate imaging reporting and data system version 2 in detecting and assessing prostate cancer lesions at prostate MRI. AJR Am J Roentgenol 2019; 212: 1197-205.